Eli Lilly scales longevity via AI drug discovery
The bull case for Eli Lilly centers on its use of AI and strategic acquisitions to lower treatment costs, triggering Jevons paradox to exponentially expand its addressable market in longevity and chronic disease.
The argument
The speaker argued that Eli Lilly is leveraging its capital to build AI labs and acquire companies to target massive chronic issues like cholesterol and obesity. By driving down the cost of these therapies, the company can dramatically increase volume and overall valuation, positioning it as a key winner in the upcoming decade of disease curation.
The thesis, stress-tested
✓ What validates it
- ✓Eli Lilly announces successful clinical milestones for its gene-editing or cholesterol pipeline
- ✓Earnings reports show volume expansion offsetting price reductions
▸ Risks discussed
- ▸Government intervention to force price caps on key drugs
- ▸Clinical trial or regulatory failures for pipeline therapies
Hear it yourself
"my latest conversation with Jordy Visser. Alright, Jordy. Let's start with the market seems to be very strong. Even when we get bad news, the market doesn't really sell off, and so it feels like there's this persistent enthusiasm now that has returned to stocks. And I recently saw that there's even, like, this retail investor, feeding frenzy. They are buying more stocks than they've ever bought before, even more than during the meme stock craze. And so, what's your take as to why is there so much almost euphoria"
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE